Desmoplastic small-round-cell tumor

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs

Retrieved on: 
Martedì, Agosto 1, 2023
Oncology, Health, Consumer, Seniors, Clinical Trials, Pharmaceutical, Biotechnology, NIDDK, Marketing, Pain, Medsafe, Adoptive cell transfer, Patient, Carcinoma, Leukemia, Prostate cancer, Disease, Human, EAP, DLBCL, SBIR, Expanded access, Physician, Bone marrow, Research, Lung cancer, Glioblastoma, CUP, Cancer, Type 1, FDA, NCI, Safety, NOD, Desmoplastic small-round-cell tumor, Multimedia, Medicine, CAR, National Cancer Institute, Animal, B-ALL, Otorhinolaryngology, Drug development, Clinical trial, NHL, National Institutes of Health, Medication, CNS, Sale, AVM, American Cancer Society, Nursing, Vaccine, Pharmaceutical industry, Medical device, TCR

Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .

Key Points: 
  • Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .
  • “AVM Biotechnology is committed to providing AVM0703 to patients who cannot participate in our enrolling clinical trial.
  • Our team at AVM Biotechnology is dedicated to providing hope to patients and their loved ones.” Theresa Deisher, AVM Biotechnology , Founder and CEO.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

LYNPARZA Market Drug Insight and Market Forecast 2023 - 2032: Detailed Descriptions of Mechanism of Action, Dosage and Administration and R&D Progress - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Febbraio 23, 2023
Pharmaceutical, Health, Oncology, Mouse Models of Human Cancer database, Clinical trial, PARP, DNA repair, Food, News, DNA, PARP3, Pancreatic cancer, ADP, DDR, Disease, Maintenance, Gene, BRCA2, Research, United Kingdom, Patient, ATM, PARP1, Enzyme, Growth, EU4, HRR, Book, Desmoplastic small-round-cell tumor, PARP2, SWOT, Olaparib, Dietary supplement, Pharmaceutical industry, Vaccine, Medical imaging

The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LYNPARZA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • "LYNPARZA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LYNPARZA for Pancreatic Cancer in the seven major markets.
  • In the DDR pathways, LYNPARZA is being tested in a range of PARP-dependent tumor types with defects and dependencies.
  • The report provides insights into:
    A comprehensive product overview including the LYNPARZA description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Retrieved on: 
Martedì, Gennaio 18, 2022
Glioma, Research, RECIST, Patient, CLPP, Forward-looking statement, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Desmoplastic small-round-cell tumor, Clinical Cancer Research, MBA, Safety, NASDAQ, Peter Anderson, GLOBE, Society, SD, ONC201, Paraganglioma, Acute myeloid leukemia, Smallpox, Wilms' tumor, American Society of Clinical Oncology, U.S. Securities and Exchange Commission, Cleveland Clinic, Company, DSRCT, DRD2, ASCO, Food, Neoplasm, Case Comprehensive Cancer Center, Sodium, Neuroblastoma, Trial of the century, KPS, Acquisition, Pharmaceutical industry, Medical imaging, Performance status, MD

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.

Key Points: 
  • ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.
  • We look forward to continuing to explore additional tumors where ONC201 may provide therapeutic benefit to existing standards of care.
  • This open-label Phase 2 investigator-initiated study treated 30 patients with rare neuroendocrine tumors.
  • A third cohort included patients with other neuroendocrine tumors, including desmoplastic small round cell tumor (DSRCT), dosed weekly with ONC201.